Obstet Gynecol Sci.  2017 Nov;60(6):587-592. 10.5468/ogs.2017.60.6.587.

Long-term recurrence-free survival of a patient with advanced pure primary ovarian squamous cell carcinoma treated with dose-dense paclitaxel combined with carboplatin

• Yazawa H
• Hiraiwa T
• Ito F
• Fujimori K

• KMID: 2418361
• DOI: http://doi.org/10.5468/ogs.2017.60.6.587

Abstract

We describe an extremely rare case of advanced pure primary ovarian squamous cell carcinoma (SCC), treated by adjuvant chemotherapy with dose-dense paclitaxel combined with carboplatin (dd-TC) plus the combination chemotherapy with irinotecan and cisplatin (CPT-P), with long-term recurrence-free survival. A 71-year-old woman complaining of lower abdominal pain was referred to our hospital and a 7-cm-diameter solid tumor was identified. She was diagnosed with a left ovarian tumor that was highly suspicious for malignancy based on ultrasonography, magnetic resonance imaging, and contrast-enhanced computed tomography. Bilateral salpingo-oophorectomy, low-anterior colon resection, and colostomy were performed. Intra- and post-operative histopathological diagnosis revealed International Federation of Gynecology and Obstetrics stage IIIc well-differentiated pure ovarian SCC. As adjuvant chemotherapy, 2 courses of dd-TC were administered, followed by 3 courses of CPT-P; the patient then underwent 4 additional courses of dd-TC. Both regimens were effective and there has been no recurrence or metastasis thus far in the 5 years since the operation.

Keyword

Ovarian neoplasms; Squamous cell carcinoma; Dose-dense therapy; Paclitaxel; Carboplatin

MeSH Terms

Abdominal Pain
Aged
Carboplatin*
Carcinoma, Squamous Cell*
Chemotherapy, Adjuvant
Cisplatin
Colon
Colostomy
Diagnosis
Drug Therapy, Combination
Epithelial Cells*
Female
Gynecology
Humans
Magnetic Resonance Imaging
Neoplasm Metastasis
Obstetrics
Ovarian Neoplasms
Paclitaxel*
Recurrence
Ultrasonography
Carboplatin
Cisplatin
Paclitaxel

Figure

• 

  Fig. 1 Magnetic resonance (A-C) and contrast-enhanced computed tomography (D) images revealed a solid tumor of the left ovary, 70×50 mm in diameter. Malignancy and adhesion to the adjacent intestine were highly suspected.

• 

  Fig. 2 Macroscopic findings of the left ovary (A) and sigmoid colon (B). Squamous cell carcinoma (SCC) directly invaded the submucosal layer of the sigmoid colon (C). Histopathologic findings of the left ovarian tumor (D, E) (objective magnification ×4 and ×20) revealed well-differentiated pure ovarian SCC.

Reference

1. Pins MR, Young RH, Daly WJ, Scully RE. Primary squamous cell carcinoma of the ovary. Report of 37 cases. Am J Surg Pathol. 1996; 20:823–833.

2. Stamp GW, McConnell EM. Malignancy arising in cystic ovarian teratomas. A report of 24 cases. Br J Obstet Gynaecol. 1983; 90:671–675.

3. Rekhi B, Parikh P, Deodhar KK, Menon S, Maheshwari A, Kerkar R, et al. Squamous carcinoma coexistent with teratoma of ovary: a clinicopathological study of 12 cases diagnosed over a 10-year period at a tertiary cancer referral center. J Cancer Res Ther. 2015; 11:211–215.

4. Kikkawa F, Nawa A, Tamakoshi K, Ishikawa H, Kuzuya K, Suganuma N, et al. Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary. Cancer. 1998; 82:2249–2255.

5. Kobayashi H, Sumimoto K, Moniwa N, Imai M, Takakura K, Kuromaki T, et al. Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer. 2007; 17:37–43.

6. Yamakawa Y, Ushijima M, Kato K. Primary squamous cell carcinoma associated with ovarian endometriosis: a case report and literature review. Int J Clin Oncol. 2011; 16:709–713.

7. Eltabbakh GH, Hempling RE, Recio FO, O'Neill CP. Remarkable response of primary squamous cell carcinoma of the ovary to paclitaxel and cisplatin. Obstet Gynecol. 1998; 91:844–846.

8. Ohtani K, Sakamoto H, Masaoka N, Shimada K, Kanaeda T, Kurihara M, et al. A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration. Gynecol Oncol. 2000; 79:515–518.

9. Park JW, Bae JW. Pure primary ovarian squamous cell carcinoma: a case report and review of the literature. Oncol Lett. 2015; 9:321–323.

10. Maruyama T, Sakai K. A case report of pure primary squamous cell carcinoma of the ovary. Jpn J Gynecol Oncol. 2009; 27:69–75.

11. Nakamura Y, Kamei T, Shinagawa M, Sakamoto Y, Miwa I. Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan. J Obstet Gynaecol Res. 2015; 41:809–812.

12. Park JY, Song JS, Choi G, Kim JH, Nam JH. Pure primary squamous cell carcinoma of the ovary: a report of two cases and review of the literature. Int J Gynecol Pathol. 2010; 29:328–334.

13. Mai KT, Yazdi HM, Bertrand MA, LeSaux N, Cathcart LL. Bilateral primary ovarian squamous cell carcinoma associated with human papilloma virus infection and vulvar and cervical intraepithelial neoplasia. A case report with review of the literature. Am J Surg Pathol. 1996; 20:767–772.

14. Shimamatsu K, Iemura A, Nakashima O, Taguchi J, Inoue M, Higaki K, et al. Squamous cell carcinoma of the ovary--a case report. Kurume Med J. 1994; 41:177–182.

15. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009; 374:1331–1338.

16. Sugiyama T, Yakushiji M, Nishida T, Ushijima K, Okura N, Kigawa J, et al. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett. 1998; 128:211–218.